^
Association details:
Evidence:
Evidence Level:
Sensitive: D – Preclinical
Source:
Title:

Targeting JAK1/2 and mTOR in murine xenograft models of Ph-like acute lymphoblastic leukemia

Published date:
10/25/2012
Excerpt:
...we determined whether rapamycin conferred a survival advantage in Ph-like ALL xenografts….Rapamycin significantly prolonged survival compared with vehicle of both xenograft IV (Figure 5A, median survival 63 days vs 23 days, P < .01) and xenograft V (Figure 5B, median survival 91 days vs 58 days, P < .01)...
DOI:
https://doi.org/10.1182/blood-2012-03-415448